BTIG Initiates Coverage On Embecta with Neutral Rating
BTIG analyst Marie Thibault initiates coverage on Embecta (NASDAQ:EMBC) with a Neutral rating.
Embecta’s Ex-Dividend Date Is Thursday, Here’s What You Need To Know
Wednesday marks the last chance for investors to receive the next dividend payout from Embecta (NASDAQ:EMBC).
Morgan Stanley Maintains Equal-Weight on Embecta, Raises Price Target to $36
Morgan Stanley analyst Cecilia Furlong maintains Embecta (NASDAQ:EMBC) with a Equal-Weight and raises the price target from $33 to $36.
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers
Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday’s Mid-Day Session
Gainers
Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New Energy effective as of August 10, 2022.
Embecta Q3 EPS $1.07 Beats $0.87 Estimate, Sales $291.10M Beat $276.86M Estimate
Embecta (NASDAQ:EMBC) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.87 by 22.99 percent. The company reported quarterly sales of $291.10 million which beat the analyst
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Why This Analyst Feels It’s Time To Short Embecta
Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ: EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.
